

Congenital Syphilis: Current epidemiology and missed prevention opportunities in Illinois

Maura Quinlan, MD MPH
Women's Health Medical Advisor

June 27, 2024




I have no financial interests to disclose



National Syphilis Data 2012-2022

FIGURE 1. Reported number of cases of congenital syphilis among infants, by year of birth, and rates* of reported cases of primary and secondary syphilis† among females aged 15–44 years, by year — United States, 2012–2022



^{*} Cases per 100,000 population.


McDonald R, O'Callaghan K, Torrone E, et al. *Vital Signs*: Missed Opportunities for Preventing Congenital Syphilis — United States, 2022. MMWR Morb Mortal Wkly Rep 2023;72:1269–1274.






Illinois Syphilis Data 1994-2022

Illinois Reported Primary and Secondary Syphilis Rates Among Women Ages 15-44 Years and Congenital Syphilis (CS) Rates, 1994 - 2022




Illinois and US Congenital Syphilis Data 2013 - 2022

Congenital Syphilis Rates, IL vs US, 2013-2022



Source: Illinois Department of Public Health

Illinois Congenital Syphilis Cases 2017 - 2023



2023 provisional data

Congenital Syphilis State Ranking 2022

Table 31. Congenital Syphilis — Reported Cases and Rates of Reported Cases by State, Ranked by Rates, United States, 2022

Rank*	State [†]	Cases	Rate per 100,000 Live Births
1	New Mexico	76	355.3
2	South Dakota	40	351.8
3	Arizona	219	281.1
4	Texas	922	246.8
5	Oklahoma	110	227.2
6	Mississippi	73	207.6
7	Louisiana	115	200.2
8	Nevada	65	193.0
9	Arkansas	69	191.9
10	Hawaii	27	172.9
11	California	616	146.5
12	Montana	15	133.6
13	Alaska	12	128.1
14	Florida	276	127.6
15	Missouri	82	118.1
	US TOTAL [‡]	3,755	102.5
16	Oregon	37	90.4
17	Georgia	101	81.4
18	West Virginia	13	75.6
19	Tennessee	61	74.6
20	Alabama	43	74.1
21	Ohio	90	69.3
22	Kentucky	35	67.0
23	Maryland	45	65.9
24	Illinois	85	64.3
25 26	Washington Colorado	52 31	62.0 49.2
27	Rhode Island	5	47.8
28	Indiana	38	47.5
29	North Carolina	57	47.3
30	New Jersey	48	47.3
31	Nebraska	11	44.7
32	South Carolina	25	43.7
33	Wisconsin	26	42.1
34	Delaware	4	38.2
35	Kansas	13	37.5
36	Michigan	36	34.3
37	Minnesota	20	31.0
38	Pennsylvania	39	29.4
39	Maine	3	25.0
40	New Hampshire	3	23.8
41	New York	50	23.7
42	lowa	8	21.7
43	Virginia	20	20.9
44	North Dakota	20	19.8
45	Connecticut	7	19.6
46	Massachusetts	11	15.9
46	Utah	7	15.0
	Idaho		
	Idaho Vermont	0	0.0 0.0





MMWR 11/2023

Morbidity and Mortality Weekly Report (MMWR)

Vital Signs: Missed Opportunities for Preventing Congenital Syphilis — United States, 2022

Early Release / November 7, 2023 / 72



Print

Robert McDonald, MD¹; Kevin O'Callaghan, MBBCh¹; Elizabeth Torrone, PhD¹; Lindley Barbee, MD¹; Jeremy Grey, PhD¹; David Jackson, MD¹; Kate Woodworth, MD²; Emily Olsen, PhD²; Jennifer Ludovic, DrPH¹; Nikki Mayes¹; Sherry Chen, MPH¹; Rachel Wingard³; Michelle Johnson Jones, MPH¹; Fanta Drame, MPH¹; Laura Bachmann, MD¹; Raul Romaguera, DMD¹; Leandro Mena, MD¹ (VIEW AUTHOR AFFILIATIONS)

View suggested citation

Summary

What is already known about this topic?

Since 2012, U.S. congenital syphilis cases increased substantially. Syphilis during pregnancy can lead to stillbirth, miscarriage, infant death, and maternal and infant morbidity, which are preventable through appropriate screening and treatment.

What is added by this report?

In 2022, lack of timely testing and adequate treatment contributed to almost 90% of congenital syphilis cases in the United States, including substantial proportions of congenital syphilis cases in all U.S. Census Bureau regions and among all racial and ethnic groups.






TABLE 1. Prenatal syphilis testing and treatment among birth parents of infants with congenital syphilis, by U.S. Census Bureau region, and by race and ethnicity — United States, 2022

	Missed opporte	unities to prevent CS, no.	(%)				
	Testing	Testing			Outcome		
Characteristic	None or nontimely*	Late identification of seroconversion [†]	Inadequate	None or nondocumented	Clinical evidence of CS despite adequate [§] prenatal treatment	Insufficient data to identify the missed opportunity	Total
All cases	1,385 (36.8)	197 (5.2)	1,494 (39.7)	423 (11.2)	130 (3.5)	132 (3.5)	3,761
U.S. Census Bureau region¶							
Northeast	83 (50.0)	25 (15.1)	26 (15.7)	14 (8.4)	11 (6.6)	7 (4.2)	166
Midwest	182 (40.4)	25 (5.5)	140 (31.0)	58 (12.9)	19 (4.2)	27 (6.0)	451

Missed Opportunities in *Chicago* 2015-2022



Search Q

Morbidity and Mortality Weekly Report (MMWR)

Notes from the Field: Diagnosis of Congenital Syphilis and Syphilis Among Females of Reproductive Age Before and During the COVID-19 Pandemic — Chicago, 2015–2022

Weekly November 24, 2023 / 72(47);1288–1289

<u>Print</u>

Helen E. Cejtin, MD^{1,2}; Eric F. Warren, MPH³; Taylor Guidry, MSPH⁴; Katherine Boss, MPH⁴; Ashley Becht, MPH⁴; Irina Tabidze, MD⁴ (VIEW AUTHOR AFFILIATIONS)



TABLE. Changes in syphilis prevalence and missed opportunities for congenital syphilis prevention — Chicago, 2015–2022



	Year, no	ο.								
	Prepandemic, 2015–2019			Pandemic, 2020–2022						
yphilis and CS characteristic	2015	2016	2017	2018	2019	Total 2015– 2019	2020	2021	2022	Total 2020– 2022
Total CS cases	24 [NA]	12 [-50.0]	11 [-8.3]	11 [—]	9 [-18.2]	67	19 [111.1]	25 [31.2]	45 [80.0]	89 [§]
Missed CS prevention opportunities (% of total)					,					
No adequate maternal treatment despite receipt of timely syphilis diagnosis	6 (25.0)	1 (8.2)	4 (36.4)	3 (23.1)	4 (44.4)	18 (26.9)	6 (31.6)	10 (40.0)	27 (60.0)	43 (48.3
No timely prenatal care and no timely syphilis testing	10 (41.7)	5 (41.7)	4 (36.4)	5 (38.5)	3 (33.3)	27 (40.3)	3 (15.8)	13 (52.0)	10 (22.2)	26 (29.2
Late identification of seroconversion during pregnancy	5 (20.8)	2 (16.7)	2 (18.2)	3 (23.1)	2 (22.2)	14 (20.9)	10 (52.6)	2 (8.0)	8 (17.8)	20 (22.5
No timely syphilis testing despite receipt of timely prenatal care	0	0	0	0	0	0 (—)	0	0	0	0 (—)
Clinical evidence of syphilis despite maternal treatment completion	3 (12.5)	4 (33.3)	1 (9.1)	0	0	8 (11.9)	0	0	0	8 (9.0)

Abbreviations: CS = congenital syphilis; NA = not applicable.



^{*} Females of reproductive age are persons aged 15–44 years and assigned female sex at birth.

[†] During 2020–2022, reported syphilis cases in females of reproductive age in Chicago increased an average of 22.1% per year.

⁵ During 2020–2022, reported congenital syphilis cases in Chicago increased an average of 74.1% per year.

Missed Opportunities Statewide 2022

	Chicago	Cook Co (Excluding Chicago)	Downstate
		(Excidenting entrange)	
	N (%)	N (%)	N (%)
Category			
Α	27 (60)	5 (50)	12 (41)
В	10 (22)	4 (40)	13 (45)
С	8 (18)	0	4 (14)
D	0	0	0
E	0	1 (10)	0

- A) No adequate maternal treatment despite receipt of timely syphilis diagnosis
- B) No timely prenatal care and no timely syphilis testing
- C) Late identification of seroconversion during pregnancy
- D) No timely syphilis testing despite receipt of timely prenatal care
- E) Clinical evidence of syphilis despite maternal treatment completion



Statewide Congenital Syphilis Mitigation Strategies





Need for Syndemic Data Collection

- Inadequate syphilis testing/treatment higher among pregnant people who reported history of
 - Incarceration
 - Being uninsured or underinsured
 - Substance use disorder
 - Unstable housing

Tannis, A., Miele, K., Carlson, J. et al, E. (2024). Syphilis Treatment Among People Who Are Pregnant in Six U.S. States, 2018–2021. *Obstetrics & Gynecology*, 143 (6), 718-729.



Illinois data modernization for improved syndemic surveillance

- New statewide IDSS system with improved linkage of data to better include variables including HIV status and substance use disorder
- Intend to develop a Master Patient Index to link patients from different data sets



New provider reporting form for perinatal syphilis (OUTSIDE Chicago)

https://redcap.link/syphreport



Clinical Information and Serology Test Results					
Latest Lab Results: * must provide value	+ RPR/VDRL + TP-PA + EIA + CIA/CMIA + CIA/CMIA + TTA-ABS - Other (Specify -RPR/ VDRL is Rapid Plasma Reagin/Venereal Disease Research Laboratory -TP-PA is Treponema Pallidum Particle Agglutination -EIA is Enzyme Immunoassay -CIA/CMIA is Chemiluminescence Immunoassay/Chemiluminescent Microparticle Immunoassay -FTA-ABS is Fluorescent Treponemal Antibody Absorption Test.				
Exam Findings and Treatment					
Exam Findings and Clinical Notes	Expand				
	Submit				



Provider resources

FUTURE DIRECTIONS IN SYPHILIS DIAGNOSIS

As described, the diagnosis of syphilis is still currently made based clinical history, physical examination, and indirect (serologic) testing. The recent evolution in syphilis serologic tests (with accompanying reverse sequence algorithm) resulted from major advances in the field over the past 20 years. The complete genome of T pallidum was sequenced in 1998.⁴⁹ This achievement spurred the development of new diagnostic techniques using recombinant treponemal antigens, such as the previously described treponemal-specific immunoassays. Admittedly, diagnostic quandaries are common, and lead to patient (and physician) distress. As our ability to study syphilis is made easier using new technologies, DNA and polymerase chain reaction-based molecular tests will likely play a role in the evolution of syphilis diagnosis over the next 20 years.⁵⁰⁻⁵²





Perinatal Syphilis Warmline Launched 11/1/2023







NEWS RELEASE

FOR IMMEDIATE RELEASE:

November 2, 2023

CONTACT:

Michael.Claffey@illinois.gov James.Leach@illinois.gov

IDPH Launches New Provider Phone Line in Response to Alarming Increase in Babies Born with Congenital Syphilis

CHICAGO – Acting to address a sharp increase in congenital syphilis cases among newborns, the Illinois Department of Public Health (IDPH) is urging healthcare providers to conduct more testing for the sexually transmitted infection in advance of birth and is launching a new phone line to provide clinical consultation for providers who treat pregnant patients and newborns.





NEWS RELEASE

FOR IMMEDIATE RELEASE:

November 2, 2023

CONTACT:

Michael.Claffey@illinois.gov James.Leach@illinois.gov

IDPH has issued a <u>letter to healthcare providers</u> in the state calling for increased awareness and testing for syphilis.

IDPH is encouraging medical providers to increase syphilis testing of all individuals - especially pregnant people - in any medical setting, including urgent care, emergency departments, and all prenatal care settings. Prenatal health care providers are required by Illinois law to screen all who are pregnant for syphilis infection at the first prenatal visit and early in the third trimester. Additional testing at the time of delivery is also recommended in high-risk settings.

The expansion of the Illinois Perinatal HIV Hotline to include the Perinatal Syphilis Warmline will provide clinical consultation for health care providers for syphilis in pregnancy and the newborn period, coordination of public health record searches to obtain prior syphilis testing and treatment information, and assistance with mandatory reporting. The warmline will be available Monday- Friday with messages returned in one business day.

Reducing syphilis cases (especially congenital syphilis) has the additional challenge of the current Bicillin shortage, the only medication that treats syphilis in pregnancy and children. Until this shortage is alleviated, it is critical that providers prioritize Bicillin inventory for treatment of those for whom there are no other treatment options: infants and those who are pregnant. Providers should consult the CDC treatment guidelines to ensure adequate care. Those who are pregnant should talk to your health care provider about testing and any needed treatment as you prepare for your baby's arrival.



Community Outreach - Chicago










Community Outreach - Statewide











Potential future efforts for CS prevention

- Mobile unit in Chicago for Bicillin treatment of pregnant people with possible partner treatment
- Enhanced case management for syphilis in pregnancy
- Expand rapid testing/treatment





Thank you for all you do!

Maura.Quinlan@Illinois.gov



